MNOV — MEDICINOVA INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1226616 ·
Last close
$1.23
Market Cap
$60.54M
52W High
$1.57
52W Low
$1.23
ADV30
26,563
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 186,984 | 16,883 | -2,835,806 | -2,586,258 | 42,704,854 | 27,329,415 | 3,297,620 |
| Dec 2025 | 151,739 | 4,754 | -3,092,402 | -2,802,279 | 45,603,109 | 30,806,477 | 4,016,428 |
| Sep 2025 | 123,319 | 8,047 | -3,380,998 | -3,050,373 | 47,578,388 | 32,562,612 | 3,613,632 |
| Jun 2025 | 134,599 | 18,250 | -3,607,092 | -3,281,185 | 49,823,875 | 34,259,637 | 2,967,006 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,496,613
Investing CF
$-13,724
Financing CF
—
CapEx
$-10,831
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.24
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-441,335,457
Inventory
—
Receivables
$245,100
ST Investments
—
EBIT TTM
$-12,916,298
Pretax Income TTM
$-11,714,101
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$596,641
EBITDA
$-12,897,116
Free Cash Flow
$-5,960,130
Enterprise Value
$33,377,916
Total Cash
$27,329,416
Total Debt
$165,198
Shares Out
49,221,246
Trailing EPS
$-0.23
Book Value
$0.80
ROE
-26.2%
ROA
-17.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 409,657 | -13,283,002 | -11,997,957 | 45,603,109 | 4,016,428 | — | -9,810,061 |
| Dec 2024 | 0 | -12,675,331 | -11,049,549 | 55,875,926 | 3,372,375 | — | -10,642,964 |
| Dec 2023 | 1,000,000 | -9,900,265 | -8,571,516 | 66,269,977 | 3,891,553 | — | -7,431,038 |
| Dec 2022 | 0 | -14,628,649 | -14,069,083 | 74,154,905 | 3,912,870 | — | -12,911,563 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.43
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.25 · call volume: 142 · put volume: 1
Expected Move to 2026-07-17:
±$1.35
(108.00%) —
implied range
$-0.10 –
$2.60
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FLNA | FILANA THERAPEUTICS, INC. | $60.38M | $1.25 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $61.74M | $0.66 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $59.20M | $1.11 | — |
| PDSB | PDS Biotechnology Corp | $58.61M | $1.05 | — |
| IBO | IMPACT BIOMEDICAL INC. | $63.08M | $0.58 | — |
News headlines (Yahoo Finance, 1h cache)
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other
2026-06-08 17:00 · Yahoo
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
2026-06-08 12:00 · Yahoo
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-05-26 23:00 · Yahoo
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
2026-05-16 12:28 · Yahoo
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
2026-04-27 23:00 · Yahoo
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
2026-03-23 13:44 · Yahoo
MediciNova to Participate at the 38th Annual ROTH Conference
2026-03-16 11:00 · Yahoo
MediciNova: Q4 Earnings Snapshot
2026-02-20 11:40 · Yahoo
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmenta
2026-02-19 08:30 · Yahoo
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
2026-01-29 23:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.